About this trial
This prospective observational cohort study aims to evaluate the association between intraoperative irrigation fluid absorption and perioperative cell-free DNA (cfDNA) dynamics in patients undergoing transurethral resection of bladder tumor (TURBT). Eligible patients with suspected or confirmed bladder cancer scheduled for TURBT will be enrolled. Intraoperative irrigation fluid absorption volume will be recorded, and peripheral blood samples will be collected before surgery and within 24 hours after surgery for cfDNA extraction and mutation analysis.
The study will assess whether irrigation fluid absorption volume is associated with changes in cfDNA concentration, tumor-related mutation detection, and clinicopathological features, including tumor stage, grade, size, number, invasion depth, concomitant carcinoma in situ, operative time, resection depth, and intraoperative blood loss. Patients will also be followed for postoperative recurrence, progression, metastasis, and other adverse oncological outcomes.
This study may provide preliminary evidence for understanding perioperative tumor-related molecular changes during TURBT and may help improve risk stratification, perioperative management, and postoperative follow-up strategies for patients with bladder cancer.
Eligibility criteria
Qualifiers
Age 18 years or older.
Suspected or histologically confirmed urothelial carcinoma of the bladder.
Scheduled to undergo TURBT.
Availability of sufficient peripheral blood samples for cfDNA extraction and mutation analysis.
Disqualifiers
Non-urothelial bladder malignancy confirmed by pathology.
History of other malignant tumors within the past 5 years, except adequately treated non-melanoma skin cancer or carcinoma in situ of the cervix.
Previous radical cystectomy or systemic antitumor therapy before enrollment.
Inadequate blood sample quality or insufficient DNA yield for mutation analysis.
Trial design
Treatments tested in this trial
- Measurement of Intraoperative Irrigation Fluid Absorption and Perioperative cfDNA Profiling
Treatment groups
Sponsors and collaborators
Zhiping Wang
Lead sponsor
Lanzhou University Second Hospital
Sponsor institution